A microRNA-based dynamic risk score for type 1 diabetes.

Summary

Using multicenter cohorts, the authors identified 50 miRNAs linked to beta-cell functional loss and built a dynamic risk score that stratified T1D with external validation (AUC 0.84). The miRNA signature predicted exogenous insulin needs post-islet transplantation and distinguished responders to imatinib.

Key Findings

• Identified 50 miRNAs associated with functional β-cell loss in T1D.
• Developed a multicontext miRNA-based dynamic risk score (n=2,204) with external validation (n=662), achieving AUC 0.84.
• Predicted future exogenous insulin requirement at 1 hour after islet transplantation.
• Baseline miRNA signature differentiated imatinib responders from nonresponders at 1 year.

Clinical Implications

Supports risk-based screening and triage for disease-modifying therapies, refines selection of candidates for interventions (e.g., islet transplantation or immune therapies), and may guide monitoring strategies.

Limitations

• Nonrandomized design; clinical utility, workflow integration, and cost-effectiveness were not tested in prospective implementation trials.
• Standardization of miRNA assays and pre-analytical handling across laboratories remains to be established.

Future Directions

Prospective implementation studies to assess clinical impact and cost-effectiveness; assay standardization; exploration of therapy selection and monitoring algorithms guided by miRNA profiles.